Table Graph
   

janus kinase (JAK) inhibitor - versus standard of care - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death or transfer to ICU 0.93 [0.87, 0.99]< 10%1 study (-/1)98.6 %NAnot evaluable crucial-
deaths 0.47 [0.28, 0.80]< 10%1 study (-/1)99.7 %NAnot evaluable crucial-
ICU admission 0.19 [0.10, 0.39]< 10%1 study (-/1)100.0 %NAnot evaluable non important-

safety endpoints 00

acute kidney injury 0.43 [0.14, 1.34]< 10%1 study (-/1)92.7 %NAnot evaluable non important-
arrhythmia 0.16 [0.03, 0.90]< 10%1 study (-/1)98.1 %NAnot evaluable non important-
elevated liver enzymes 0.52 [0.18, 1.51]< 10%1 study (-/1)88.5 %NAnot evaluable non important-
Myocardial infarction 0.87 [0.19, 3.92]< 10%1 study (-/1)57.2 %NAnot evaluable non important-
venous thromboembolism 5.23 [0.42, 65.62]< 10%1 study (-/1)10.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons